Schering strengthened by $180 million acquisitionCorporate alliances that defined the landscape of diagnostic imaging'sCT contrast injector market were shaken last week when marketleader Medrad accepted a $180 million tender offer from ScheringAG
The acquisition of Medrad was widely seen as a victory in Schering'seffort to become more prominent in the U.S. x-ray contrast agentmarket. The opening salvo came earlier this year when the Foodand Drug Administration cleared its nonionic agent, Ultravist(SCAN 6/7/95).
By purchasing Medrad, Schering gains direct access to the largeand swiftly growing spiral CT market. Contrast media used in theseand an increasing number of general CT and x-ray angiographicapplications are administered by automated injector. About 60%of U.S. CT suites are equipped with the devices, and the percentageis growing, according to Thomas H. Witmer, chief executive ofMedrad.
Moreover, the nonionic contrast media administered in thismanner are prepackaged using patented syringes and connectorsthat have been licensed to the contrast manufacturers. The marketis split between Medrad and Liebel Flarsheim in Cincinnati.
Medrad dominates the two-company field, with alliances withBracco (Isovue nonionic contrast) and Nycomed Imaging (Omnipaquenonionic contrast). It has a worldwide installed base of 17,000injectors, Witmer said.
Mallinckrodt Medical in St. Louis -- the third largest makerof nonionic contrast -- is not licensed to prepackage its contrastagent for administration with this equipment. It is allied withLiebel Flarsheim.
Publicly traded Medrad reported sales of $78.3 million fromits contrast injector and MR coil businesses in the year endedJan. 31. Sales rose 15% to $40 million for the first half of fiscal1995. Net earnings for the period were $3 million, a 30% gainfrom the first half of 1994.
Schering will pay cash for all outstanding Medrad stock, accordingto Witmer. Shareholders have 20 days from August 23 to tendertheir shares, he said.
The benefit of synergy. Why would Medrad risk its comfortableposition to become a subsidiary of Schering of Berlin?"Themain interest here is synergy of technologies and projects,"Witmer said.
He is banking on the relationship with Schering to propel Medradto additional sales in Europe and Japan. With worldwide salesof $2.9 billion, Schering is a formidable player in both regions.
Witmer envisions a large market developing for MR contrastinjection in the U.S. Through its Berlex licensee, Schering isby far the predominant force in MR contrast. Spectris, Medrad'snew MR contrast injector, will be introduced late this fall, Witmersaid.
Automated injection is a new concept for MR, but Witmer contendsthat it will catch on quickly, especially in MR angiography andcomplex procedures requiring multiple contrast administrations.
"There has been tremendous customer interest in Spectris;we could sell a bundle of them, if we had them now," he said.
With the deal with Schering only days old, it remains to beseen if Bracco and Nycomed Imaging officials can work with Medradunder Schering ownership.
Witmer had yet to break the news of the Schering purchase toBracco and Nycomed when he talked with SCAN. He conceded thatdelicate negotiations lay ahead.
"We will with complete ethics uphold our end of the bargainfor development programs relating to prefilling our syringes withtheir contrast. We will honor the contracts completely,"he said.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
Chest CT Study Shows Higher Emphysema Risk from Combination of Marijuana and Cigarette Smoking
November 28th 2023People who smoke marijuana and cigarettes have 12 times the risk for centrilobular emphysema than non-smokers, according to new computed tomography (CT) research presented at the annual Radiological Society of North America (RSNA) conference.